Class II compounded GLP-1 recalls, Oct 2026

Two firms, one report date

FDA's enforcement definitions say Class II is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Ongoing means a recall which is currently in progress. The recall initiation date is the date the firm first began notifying the public or its consignees. Both events below are voluntary and firm-initiated. FDA classified them on 8 October 2026 and the report date is 14 October 2026.

Distribution for both is nationwide in the United States. FDA's definition of distribution pattern says subsequent distribution by the consignees to other parties may not be included. The product records name the recalling firm and the product. They do not name a telehealth platform, a clinic, or a website that sold the lots.

These rows are the enforcement records. They are not a finding that a commission-earning provider on this site dispensed either firm's lot.

Lot codes to compare with a label

FDA defines code information as the lot and serial numbers, product numbers, and expiration or use-by dates that appear on the product or its labeling. The tables quote those fields. A label that names a different pharmacy is not on these two lists. A label that names one of these firms still has to match a lot below. The Apothecary tirzepatide list runs from lot AP-202622 through AP-202644 and does not include a line for AP-202626.

Apothecary D-0036-2027 lots, as printed: AP-202622, BUD 07-Oct-2026; AP-202623, BUD 08-Oct-2026; AP-202624, BUD 19-Oct-2026; AP-202625, BUD 10/20/2026; AP-202627, BUD 10/26/2026; AP-202628, BUD 10/27/2026; AP-202629, BUD 10/28/2026; AP-202630, BUD 10/31/2026; AP-202631, BUD 11/01/2026; AP-202632, BUD 11/03/2026; AP-202633, BUD 11/07/2026; AP-202634, BUD 11/08/2026; AP-202635, BUD 11/16/2026; AP-202636, BUD 11/17/2026; AP-202637, BUD 11/18/2026; AP-202638, BUD 11/19/2026; AP-202639, BUD 11/20/2026; AP-202640, BUD 11/21/2026; AP-202641, BUD 11/22/2026; AP-202642, BUD 11/24/2026; AP-202643, BUD 11/25/2026; AP-202644, BUD 11/26/2026.

The same events also list other products

Event 99867 has sixteen product recalls, D-0017-2027 through D-0032-2027. Eight are the GLP-1 rows above. D-0020-2027 is sermorelin acetate 1 mg/mL injectable, 15 mL in patient-specific syringes, lots 07292026@12, BUD 09/12/2026, and 07302026@7, BUD 09/13/2026. Its reason text is the same sterility wording as the GLP-1 rows. D-0021-2027 is titled QUAD-MIX( PAPAV/PHENTO/ALPROS/TROP). D-0022-2027 through D-0025-2027, D-0031-2027, and D-0032-2027 are titled Tri-MIX (PAPAV/PHENTO/ALPROS). Those mix rows are in the same event file. This article does not repeat their lot lists.

Event 99952 has a second product. D-0037-2027 is Apothecary NAD+ Injection 200 mg/mL, 6 mL sterile multi-dose vial, NDC 85091-011-06, quantity 1 vial, lot AP-202647, BUD 13-Oct-2026. Same classification, dates, and reason as the tirzepatide vial. A NAD+ price on this site is not a statement that the vial came from Apothecary Pharma.

Numbers D-0017-2027 through D-0030-2027 are one Carolina event, not eight GLP-1 recalls only. Read the product name before treating a number as semaglutide or tirzepatide.

What a named pharmacy lets you compare

FDA's page on unapproved GLP-1 drugs says to contact the compounder who made the drug, or the telehealth platform where you bought it, with questions about the instructions or the information on the label. The practical comparison is whether a provider's own page names the pharmacy you would call. The pages below were opened on 21 October 2026. They are commission-earning providers. A page that names a pharmacy still does not say which of those pharmacies filled a particular past prescription.

SnagRX's semaglutide page lists four partner pharmacies: Red Rock Compounding Pharmacy in St. George, Utah; Health Warehouse in Florence, Kentucky; Precision Medicine in Bellmore, New York; and Triad Rx in Daphne, Alabama. The page says the prescription may involve any one or more of them. None of those four names is Carolina Infusion or Apothecary Pharma. That is a statement about the partner list on the page, not a history of every fill.

USA Today reported on 20 October 2026 that it is unclear which marketers sold Apothecary Pharma's tirzepatide injections. The openFDA product text agrees with the narrower point: the recalling firm is named, and a telehealth brand is not. USA Today also quoted Erin Fox, senior pharmacy director at University of Utah Health: "If it's just for price point, than it's absolutely buyer beware because you get what you pay for." The spelling "than" is the article's. This page does not use that sentence as a ranking.

Ask the pharmacy printed on your own label. A partner list on a marketing page is not a substitute for that label, and it is not a recall clearance.

What FDA's GLP-1 page says, separate from these lots

FDA's concerns page says unapproved versions of GLP-1 drugs do not undergo FDA's review for safety, effectiveness, and quality before they are marketed. It says compounded drugs are not FDA-approved, and that compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug. It says patients should get a prescription from their doctor and fill it at a state-licensed pharmacy. Those sentences are about compounded GLP-1 drugs as a category. They are not a description of Carolina Infusion lot 08262026@6 or Apothecary lot AP-202622.

The package difference matters for one FDA recommendation on that page. Carolina's recalled GLP-1 products are single-use syringes. Apothecary's recalled tirzepatide is a 4 mL multi-dose vial. FDA says it generally recommends that vials containing multiple doses of sterile medications be used within 28 days after the first use, and that a consumer discard the vial within 28 days after first use even if medication remains, including when a compounder's instructions say it can be used longer. That is FDA's general recommendation. The enforcement record's own beyond-use dates are the dates in the lot table.

The same FDA page says that as of 31 May 2026 it had received 990 reports of adverse events associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. It says it is not always possible to determine whether the event resulted from the drug, and that state-licensed pharmacies that are not outsourcing facilities are not required to submit adverse events, so the counts are likely underreported. Those counts are not attached to event 99867 or event 99952 in the files opened for this article. The page also describes a green-list import alert, number 66-80. That is a different document from this site's note on import alert 66-40.

FDA asks patients, health professionals, and compounders to report adverse events or quality problems to MedWatch. The page lists druginfo@fda.hhs.gov and 855-543-3784 for the CDER Office of Drug Information.

This comparison does not say whether a particular vial is safe to use. Questions about a label go to the dispensing pharmacy, the prescriber, or the contact FDA names.

A later report names a different firm

The tables above are the 14 October 2026 openFDA file. On 22 October 2026, FDA's public Enforcement Report listed a separate event, 99990, for Houston Rx LLC of Houston, Texas. That record is not in the openFDA tirzepatide search used here, whose newest tirzepatide report date was still 14 October 2026. Event 99990 is Class II. The firm initiated it on 25 September 2026, and the enforcement report date is 21 October 2026.

Recall D-0040-2027 is 64 vials of tirzepatide/niacinamide, lot TZN-080326-20/2-2, beyond-use date 12/01/2026, for lack of assurance of sterility. The same event lists 7 vials of sermorelin as D-0041-2027. The record does not name a telehealth brand. The lot list and the pharmacy comparison for that event are on the news note. This page does not repeat them, and it does not say that a provider in the table above used Houston Rx LLC.